Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: meta-analyses of published studies

Madan G. Kundu and Suddhasatta Acharyya

Novartis Pharmaceutical Corporation East Hanover, NJ, USA

Abstract

Purpose: PFS is often used as a surrogate endpoint for OS in metastatic breast cancer studies. We have evaluated the association of treatment effect on PFS with significant HR*OS* (and how this association is affected by other factors) in published prospective metastatic breast cancer studies.

Methods: A systematic literature search in PubMed identified prospective metastatic breast cancer studies. Treatments effects on PFS were determined using hazard ratio (HR_{*PFS*}), increase in median PFS ($\triangle \text{MED}_{PFS}$) and % increase in median PFS (% $\triangle \text{MED}_{PFS}$). Diagnostic accuracy of PFS measures (HR_{PFS}, ∆MED_{PFS} and %∆MED_{PFS}) in predicting significant HR_{OS} was assessed using receiver operating characteristics (ROC) curves and classification trees approach.

Results: Seventy-three cases (i.e., treatment to control comparisons) from 64 individual publications were identified for the analyses. Of these, 16 cases reported significant treatment effect on HR_{OS} at 5% level of significance. Median number of deaths reported in these cases were 156. Area under the ROC curve (AUC) for diagnostic measures as HR_{PFS} , $\triangle \text{MED}_{PFS}$ and $\% \triangle \text{MED}_{PFS}$ were 0.69, 0.70 and 0.75, respectively. Classification tree results identified %∆MED_{*PFS*} and number of deaths as diagnostic measure for significant HR_{OS}. Only 7.9% (3/38) cases with $ΔMED_{PFS}$ shorter than 48.27% reported significant HR_{OS}. There were 5 cases with ΔMED_{PFS} greater than 98.69% and number of deaths reported as 227 or more – all of these 5 cases reported significant HR*OS*.

Conclusion: %∆MED_{*PFS*} was found as better diagnostic measure for significant HR_{OS}. Our analysis results also suggest that consideration of total number of deaths may further improve its diagnostic performance.

Keywords: Metastatic breast cancer, Progression free survival, Overall survival, surrogacy, metaanalysis, ROC curve, classification tree

Introduction

As per national cancer institute, in the U.S., breast cancer is the second most common non-skin cancer and the second leading cause of cancer-related death in women; and, therefore, there has always been a high demand for novel breast cancer therapies. At the time of preparing this manuscript, 175 phase III breast cancer studies were actively recruiting patients. For breast cancer therapies, the main goal is to improve overall survival and quality of life [\[1,](#page-8-0) [2\]](#page-8-1). US FDA guideline [\[3\]](#page-8-2) states that "[overall] survival is considered the most reliable cancer endpoint". Due to the advancement in metastatic breast cancer management and therapies, there has been marked improvement in overall survival in breast cancer patients in the last few decades. As a result, there are practical limitations

including the need of larger sample size and larger follow-up time [\[4\]](#page-8-3) and, surrogate endpoints such as progression-free survival (PFS) or objective response rate (ORR) are being increasingly used for accelerated approvals, with PFS being the one used most often [\[1\]](#page-8-0). The basis for using PFS as surrogate endpoint for OS is as follows: cancer progression represents an ominous march toward death from malignancy. Hence, longer it takes the cancer to progress, the longer a patient will live [\[5\]](#page-8-4). However, PFS has not been statistically validated for surrogacy of OS yet [\[1,](#page-8-0) [3\]](#page-8-2).

According to Prentice's definition[\[6\]](#page-8-5), in order PFS to be a "statistically validated" surrogate endpoint for OS, "test for null hypothesis of no treatment effect in PFS" should be a valid "test for null hypothesis of no treatment effect in OS". The test for treatment effect on OS is carried out by testing HR*OS*=1, where HR*OS* is the hazard ratio (HR) of overall survival. However, many randomized clinical trials failed to demonstrate significant treatment effect in OS despite demonstrating significant treatment effect in PFS. The current project attempts to investigate this from a diagnostic testing perspective, using nonparametric receiver-operating characteristic (ROC) curves and classification tree. It is important to note that our investigation differs from previous investigations [\[7,](#page-8-6) [8,](#page-8-7) [9,](#page-9-0) [10,](#page-9-1) [12,](#page-9-2) [13,](#page-9-3) [14,](#page-9-4) [11\]](#page-9-5) based on meta-analytic methods, where the primary purpose was to examine the strength of treatment effect on PFS to predict treatment effect on OS at trial level. The analysis formulation in the current investigation is intuitive and aligned with the ultimate question that all stakeholders, regulators in particular, are often seeking an answer to, from a phase III cancer clinical trial – Is there a statistically significant overall survival benefit in the new treatment that is discernible from the data on progression-free survival (PFS) in metastatic breast cancer studies?

We have used nonparametric receiver-operating characteristic (ROC) curves and classification tree approach to address this question. Both the approaches are non-parametric and are free from the often unverifiable modeling assumptions of the standard meta-analytic methods. Further, classification tree results are easy to interpret, and offers granular visualization of the results. We have utilized classification tree to answer following questions: (a) which trial level measure of treatment benefit in PFS has stronger association with significant HR*OS* (HR of OS) in favor of treatment – HR_{PFS} (HR of PFS) or $(\%)$ median improvement in PFS? (b) Is there any other factor(s) (e.g., total number of deaths) that influence significance of HR_{OS} ? (c) if yes, then how this measure modifies the association of treatment benefit in PFS with significant HR*OS*? For this project, breast cancer studies were our focus, but the similar investigation can be carried out for other indications as well. Throughout the article, (unless otherwise mentioned), 'statistically significant' would imply that the significance was in favor of the treatment.

Methods

Literature search

A systematic literature search in PubMed (July 2015) was performed to identify published prospective studies on metastatic breast cancer research with both PFS and OS comparison results reported. The search criteria were as follows: (i) title includes the phrase "breast cancer", (ii) the term "randomized" is in title or abstract, (iii) the phrase "progression free survival" and "overall survival" are mentioned in the text [criteria: Breast cancer (in Title), Randomized (in Title or Abstract), Progression free survival (in Text Word) and Overall survival (in Text Word)]. The PubMed search returned 181

Journal of Publication	2014-2015		2012-2013 2010-2011	2005-2009	2000-2004	Total
Journal of Clinical Oncology					3	28
Breast Cancer Research						
Treatment						10
Annals of Oncology						
Cancer						
Clinical Breast Cancer			3			
Clinical Cancer Research						
Others						
Total		20	13			64

Table 1: Summary of publications by journal and year

publications between Jul-2000 and Jul-2015. Many of these studies were systematic literature review or meta-analyses and hence dropped. Further, studies with either PFS or OS not reported were also excluded. In one publication, instead of PFS, time to progression (TTP) was reported and that study was dropped. Finally, we were able to find 64 individual prospective studies [\[15,](#page-9-6) [16,](#page-9-7) [17,](#page-9-8) [18,](#page-9-9) [19,](#page-9-10) [20,](#page-10-0) [21,](#page-10-1) [22,](#page-10-2) [23,](#page-10-3) [24,](#page-10-4) [25,](#page-10-5) [26,](#page-10-6) [27,](#page-10-7) [28,](#page-11-0) [29,](#page-11-1) [30,](#page-11-2) [31,](#page-11-3) [32,](#page-11-4) [33,](#page-11-5) [34,](#page-11-6) [35,](#page-11-7) [36,](#page-11-8) [37,](#page-11-9) [38,](#page-12-0) [39,](#page-12-1) [40,](#page-12-2) [41,](#page-12-3) [42,](#page-12-4) [43,](#page-12-5) [44,](#page-12-6) [45,](#page-12-7) [46,](#page-12-8) [47,](#page-13-0) [48,](#page-13-1) [49,](#page-13-2) [50,](#page-13-3) [51,](#page-13-4) [52,](#page-13-5) [53,](#page-13-6) [54,](#page-13-7) [55,](#page-13-8) [56,](#page-13-9) [57,](#page-14-0) [58,](#page-14-1) [59,](#page-14-2) [60,](#page-14-3) [61,](#page-14-4) [62,](#page-14-5) [63,](#page-14-6) [64,](#page-14-7) [65,](#page-14-8) [66,](#page-15-0) [67,](#page-15-1) [68,](#page-15-2) [69,](#page-15-3) [70,](#page-15-4) [71,](#page-15-5) [72,](#page-15-6) [73,](#page-15-7) [74,](#page-15-8) [75,](#page-16-0) [76,](#page-16-1) [77,](#page-16-2) [78\]](#page-16-3) where both PFS and OS comparison results were reported. The majority of these articles were published in the Journal of Clinical Oncology (28; 43%), Annals of Oncology (10; 15%) and Breast cancer research treatment (10; 15%) Table [1.](#page-2-0) Majority (43, 67%) of these studies recruited patients to treat as first line therapy. Forty (63%) of these studies where phase III. In 59 studies comparison was made with active control, in 2 studies comparison was made with placebo and in remaining 3 studies standard care was used as comparator.

Data extraction

In seven prospective studies [\[20,](#page-10-0) [21,](#page-10-1) [22,](#page-10-2) [47,](#page-13-0) [58,](#page-14-1) [77,](#page-16-2) [78\]](#page-16-3), two pairs of treatment-to-control comparisons were made and in one prospective study [\[19\]](#page-9-10), three pairs of treatment-to-control comparison was made. Therefore, we had total of 73 treatment-to-control comparison available for the meta-analyses. For each treatment-to-control comparisons, following information were extracted: randomization status, blinding status (open or blinded), total sample size (treatment plus control), total number of events (treatment plus control), median PFS, median OS, HR (hazard ratio) in PFS (HR_{PFS}), HR in OS HR_{OS}, reported p-value (or significance status) for HR_{PFS} and reported p-value (or significance status) for HR*OS*. In case both local and central PFS assessments were reported, the one which was reported as primary endpoint was considered.

Statistical methods

Treatments effects on PFS were determined using following comparative measures: hazard ratio (HR_{PFS}), increase in median PFS ($\triangle \text{MEDPFS}$) and % increase in median PFS (% $\triangle \text{MEDPFS}$). All these 3 comparative PFS measures were used as diagnostic measures for predicting statistically significant HR*OS* in favor of treatment (yes/no).

Diagnostic accuracy of comparative PFS measures (HR_{PFS}, ∆MED_{PFS} and %∆MED_{PFS}) in predicting significant HR*OS* was assessed using ROC curve [\[79\]](#page-16-4) based on logistic regression and classification tree (CART) [\[80\]](#page-16-5) approaches. Empirical ROC curves were drawn plotting the true positive rate (proportion of correct prediction of significant HR*OS* based on comparative PFS measure among those reporting significant treatment effect on HR*OS*) against the false positive rate (proportion of wrong prediction of significant HR*OS* based on PFS measure among those reported non- significant treatment effect on HR*OS*). The accuracy of the diagnostic measure was assessed by numerically computing the area under ROC curve (AUC), with larger AUC implying better accuracy. Optimal cut-off points based on ROC curve were identified according to Youden's index[\[81\]](#page-16-6). According to Youden's criteria a optimum cut-off point for prediction of significant HR_{OS} would be one that maximizes the difference between true positive rate and false positive rate.

For classification tree analyses, following variables were used as partitioning variables: all 3 comparative PFS measures (HR_{*PFS*}, ∆MED_{*PFS*} and %∆MED_{*PFS*}), total number of patients and total number of deaths. *Bagging* method was applied to identify the most important partitioning variable(s). All statistical analyses were performed using R 3.0.2. A two-sided p value of *<* .05 was considered statistically significant. ROC analysis was done using "ROCR" package [\[82\]](#page-16-7). Classification tree was constructed using "rpart" package [\[83\]](#page-16-8) and for *bagging* method we have used "randomForest" package [\[84\]](#page-16-9).

Results

Description

Seventy-three treatment-to-control comparisons from 64 publications were identified for the analyses. Characteristics of these comparisons are summarized in Table [2.](#page-4-0) Of 73 comparisons, 72 (98.6%) were made in randomized set-up and 46 (63.0%) were based on phase III trials. Only 15 (20.5%) comparisons were reportedly carried out in blinded fashion and for 20 (27.4%) comparisons, blinding status was not reported. The median total sample size was 231 and the median number of deaths reported was 59. The median HR_{PFS} and HR_{OS} were 0.78 and 0.85, respectively. Further, on average, median PFS times was increased by 1.60 months which translates to 28.41% increase in median PFS time.

Of the 73 comparisons, significant (at 5% level) HR_{PFS} and HR_{OS} were reported in 32 (43.8%) and 16 (21.9%) cases, respectively (see Table [3\)](#page-4-1). The comparisons with significant HR_{PFS} are 5.55 times more likely to have significant HR_{OS} compared to the cases where HR_{PFS} was not reported as significant. However, more importantly, only 37.5% (12/32) of comparisons with significant HR_{PFS} also reported significant HR*OS*.

Diagnostic accuracy (using ROC analysis)

Each of HR_{OS} (p − value=0.0447), \triangle MED_{*PFS*} (p − value=0.0109) and % \triangle MED_{*PFS*} (p − value=0.0189) were found as significant diagnostic measure for predicting odds of significant HR*OS* in separate logistic regression analyses considering each comparative PFS measure as only predictor at a time. AUC from ROC curves based on diagnostic measure of HR_{PFS} (AUC=0.69) and ΔMED_{PFS} (AUC=0.70) were numerically very close. However, % ΔMED_{PFS} offers relatively better diagnostic accuracy with

Characteristics	
Study phase $-\operatorname{n}(\%)$	
Phase III	46 (63.0%)
Phase II/IIB	$19(26.0\%)$
Unknown	$8(11.0\%)$
Randomization status – $n(\%)$	
Randomized	72 (98.6%)
Unknown	$1(1.4\%)$
Blinding status – $n(\%)$	
Open	$38(52.1\%)$
Blinded	$15(20.5\%)$
Unknown	$20(27.4\%)$
Sample size $(n=73)$	
Median (Min, Max)	231 (41, 1349)
Number of deaths $(n=59)$	
Median (Min, Max)	156(19, 997)
Increase in median PFS, ΔMED_{PFS} (n=71)	
Median (Min, Max)	1.60 (-0.50 , 10.90)
$\%$ increase in median PFS, $\% \Delta \text{MED}_{PFS}$ (n=71)	
Median (Min, Max)	28.41 (-10.42, 294.60)
HR in PFS, HR_{PFS} (n=67)	
Median (Min, Max)	0.78 $(0.24, 1.18)$
HR in OS, HR_{OS} (n=62)	
Median (Min, Max)	0.85(0.37, 1.49)

Table 2: Summary of 73 cases (i.e. treatment to control comparisons) included in the meta-analyses

Table 3: Number of cases (i.e. treatment to control comparisons) reporting significant (at 5% level) difference in PFS and OS time

	Overall survival (OS)		
Progression free survival (PFS) HR_{OS} significant HR_{OS} not significant			
HR_{PFS} significant			
HR_{PFS} not significant		37	
Level of significance is 5% .			

Figure 1: ROC curves using treatment effect on PFS as diagnostic measure for prediction of significant HR*OS* at 5% level of significance. Treatments effects on PFS were assessed using (a) hazard ratio (HR_{PFS}), (b) increase in median PFS ($\triangle \text{MED}_{PFS}$) and (c) % increase in median PFS (%∆MED_{PFS}). True positive rate was defined as proportion of correct prediction among the cases reported significantHR*OS*). False positive rate was defined as (% of wrong prediction among the cases reported non- significant HR*OS*).

Figure 2: Classification tree in predicting significant treatment effect on OS

AUC as 0.75.

From the ROC curve of %∆MED_{*PFS*} in Figure 1c, the optimal cut-off point (according to Youden's index) is 44.83%, for which the sensitivity (i.e. true positive rate) is 81.3% and specificity (i.e. 1 false positive rate) 76.4%. It can be interpreted as follows: if we set a predictive rule to classify the cases with improvement in median PFS greater than 44.83% as producing significant HR*OS* subsequently, then 81.3% of cases reporting significant HR*OS* will be correctly predicted and 76.4% of cases reporting non-significant HR*OS* will be correctly predicted. Another cut-off point of interest could be 33.33% for which the sensitivity is 87.5% and specificity 63.6%.

Diagnostic accuracy (using classification tree)

In classification tree approach, in addition to comparative PFS measures, number of deaths and sample size were also considered as predictor variables. Classification tree results based on 73 cases (i.e. comparisons) identified %∆MED_{PFS} and total number of deaths as diagnostic measures for significant HR_{OS}. Importantly, we found %∆MED_{*PFS*} as most important predictor variable compared to HR_{PFS} or ∆MED_{PFS}. This is very much consistent with our findings observed in the analysis based on the ROC curve. The *bagging* method also suggested that %∆MED_{*PFS*} as the most important and total number of deaths as the second most important diagnostic measures for significant HR*OS*

Next, we performed classification tree analysis only on the 57 cases where information available for both %∆MED_{PFS} and total number of deaths. The classification tree results are displayed in Figure [2.](#page-6-0) In 38 cases, increases in median PFS were shorter than 48.27%; and only 3 of these cases showed significant HR*OS*. In 5 cases, increases in median PFS were between 48.27% and 98.69%; and only one of them produced significant HR*OS*. There were 14 cases with increases in median PFS reported at least 98.69%. Of these 14 cases, in 9 cases total deaths were reported less than 227 and 4 of them reported significant HR_{OS} . In remaining 5 cases total deaths were 227 or more and all of them reported significant HR*OS*.

The findings of Figure 2 can be summarized as follows: when increase in median PFS is less than

48.27%, it is unlikely that study would produce significant HR*OS*. When increase in median PFS equals or exceeds 98.69%, and minimum number of deaths is 227 or more then there is greater likelihood to obtain significant HR*OS*.

Discussion

That a substantial improvement in PFS should be predictive of a corresponding difference in OS makes common sense. However, what is often not obvious is the magnitude of PFS difference that is required to be reasonably confident of observing a statistically significant HR*OS*. This is crucial in late phase trials where therapeutic agents are being tested and the sponsor needs to decide whether the observed PFS difference could be predictive of a significant and clinically meaningful difference in OS and would merit a marketing authorization application (MAA). The ROC and classification tree analyses employed here are very well suited for such a determination. For example, ROC approach gives us an overall assessment of diagnostic accuracy based on the AUC metric. On the other hand, tree approach is helpful in identifying non-linear association and influence of other factor, such as total number of death, in an interpretable and visible manner. Both the approaches help us to choose an optimal operating point to guide the decision-making process.

Our study findings can be summarized as follows: First of all, ΔMED_{PFS} (i.e. percentage difference in median PFS) is a relatively better diagnostic predictor compared to HR_{PFS} . This is suggested by both ROC analysis and classification tree analyses. Secondly, higher %∆MED_{*PFS*} tends to be associated with significant HR*OS*. However, our classification tree result suggests that higher number of deaths is also important in achieving significant HR*OS*. The fact that number of death influencing result of statistical testing of HR*OS* is very logical as deaths are considered as events in OS analysis and increased number of events improves the chance of statistical significance [i.e., power] in survival analyses.

There have been numerous studies examining the strength of surrogacy and the ability of a surrogate measure such as PFS to predict OS. Most of the previous meta-analytic studies on metastatic breast cancer attempted to measure the association between improvement in OS with improvement PFS and clinical benefit rate (CBR) [\[7,](#page-8-6) [8,](#page-8-7) [9,](#page-9-0) [10,](#page-9-1) [12,](#page-9-2) [13\]](#page-9-3). For example, Miksad *et al.* [\[9\]](#page-9-0) found only moderate correlation between HR_{PFS} and HR_{OS} (R^2 ranging between 0.35 to 0.59) in taxane and anthracycline based therapies in breast cancer patients. Recently, Amiri-Kordestani *et al.* (2016) [\[11\]](#page-9-5) reported a moderate association between odds ratio (OR) of CBR and HR_{PFS} ($R^2 = 0.52$), but failed to show any association with OR of CBR with HR_{OS} ($R^2 = 0.01$) from 13 prospective studies submitted to FDA. Our work takes a markedly different path. First, we are interested in assessing the association of treatment effect on PFS with the ultimate interest being the observance or nonobservance of a significant HR*OS*, whereas previous meta-analyses were more focused on exploring the association between the treatment effects on PFS and OS. Secondly, we have also considered PFS measures beyond HR_{PFS} such as ∆MED_{PFS} (i.e. difference in median PFS) or %∆MED_{PFS} (i.e., percentage difference in median PFS). Thirdly, we have used fully data dependent non-parametric approaches like empirical ROC curves and classification trees for the meta-analyses which, as far as we know, has not been used before in applications of this type. Fourthly, we have also included other factors such as total sample size and total number of death in evaluating the association between PFS measures and significance of HR*OS*. Last but not the least, we have included a comprehensive list of all published studies since 2000 and hence number of studies included in this current investigation is relatively higher than previous published meta-analyses.

Our study has its limitations. Not all breast cancer studies published during the period under consideration could be included, although the number is still quite high compared to previous meta analyses. The selection of studies was driven by common-sense but objective search criteria which were rigorously applied. Thus, only 73 treatment to control comparisons from 64 prospective published trials on breast cancer met the eligibility. The included trials were diverse in nature in terms of patient population considered – some examples of patient population are metastatic or advanced breast cancer patients, patients with at least two prior chemotherapies, anthracycline or taxane resistant patients, post-menopausal patients, HER2 positive patients, HER2 negative patients, just to name a few. Thus, although the results are generalizable to the overall breast cancer population, they may not be applicable to all niche breast cancer populations. There is also potential for publication bias. To minimize the publication bias, we have considered all the studies which were published and listed in PubMed database and met our search criteria. Lastly, we have not looked into other cancer indications, although we cannot think of any reason why the method would not be a useful tool in assessing surrogacy of PFS (or any other continuous time-to-event endpoint, or that matter)

To conclude, empirical ROC curves and classification trees could be useful tools for assessing how well treatment effect on PFS predicts HR_{OS} in breast cancer studies.

References

- [1] Saad, E., Katz, A., Hoff, P., and Buyse, M. (2010). Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. *Annals of oncology*, $21(1):7-12.$
- [2] Smith, I. (2006). Goals of treatment for patients with metastatic breast cancer. In *Seminars in oncology*, volume 33, pages 2–5. Elsevier.
- [3] FDA CDER and CBER (May 2007). Clinical trial endpoints for the approval of cancer drugs and biologics.
- [4] Booth, C. M., and Eisenhauer, E. A. (2012). Progression-free survival: meaningful or simply measurable?. *Journal of Clinical Oncology*, 30(10), 1030-1033.
- [5] Venook, A. P. and Tabernero, J. (2014). Progression-free survival: Helpful biomarker or clinically meaningless end point? *Journal of Clinical Oncology*, pages JCO–2014.
- [6] Prentice, R. L. (1989). Surrogate endpoints in clinical trials: definition and operational criteria. *Statistics in medicine*, 8(4):431–440.
- [7] Bruzzi, P., Del Mastro, L., Sormani, M. P., Bastholt, L., Danova, M., Focan, C., and others. (2005). Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. *Journal of clinical oncology*, 23(22), 5117-5125.
- [8] Hackshaw, A., Knight, A., Barrett-Lee, P., & Leonard, R. (2005). Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. *British journal of cancer*, 93(11), 1215-1221.
- [9] Miksad, R. A., Zietemann, V., Gothe, R., Schwarzer, R., Conrads-Frank, A., Schnell-Inderst, P., and others (2008). Progression-free survival as a surrogate endpoint in advanced breast cancer. *International journal of technology assessment in health care*, 24(04), 371-383.
- [10] Sherrill, B., Amonkar, M., Wu, Y., Hirst, C., Stein, S., Walker, M., and Cuzick, J. (2008). Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. *British journal of cancer*, 99(10), 1572-1578.
- [11] Amiri-Kordestani, L., Cheng, J., Zhang, L., Tang, S., Sridhara, R., Ibrahim, A., · · · & Pazdur, R. (2016, May). Association of clinical benefit rate (CBR) with survival: A pooled-analysis of metastatic breast cancer (MBC) trials submitted to the US Food and Drug Administration (FDA). *In ASCO Annual Meeting Proceedings*, Vol. 34, No. 15 suppl, p. e18091).
- [12] Burzykowski, T., Buyse, M., Piccart-Gebhart, M. J., Sledge, G., Carmichael, J., LÃijck, H. J., ... & Jassem, J. (2008). Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. *Journal of Clinical Oncology*, 26(12), 1987-1992.
- [13] Ng, R., Pond, G. R., Tang, P. A., MacIntosh, P. W., Siu, L. L., and Chen, E. X. (2008). Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. *Annals of oncology*, 19(3), 481-486.
- [14] Sherrill, B., Kaye, J. A., Sandin, R., Cappelleri, J. C., and Chen, C. (2012). Review of metaanalyses evaluating surrogate endpoints for overall survival in oncology. Onco Targets Ther, 5, 287-296.
- [15] Wang, J., Xu, B., Yuan, P., Ma, F., Li, Q., Zhang, P., Cai, R., Fan, Y., Luo, Y., and Li, Q. (2015). Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. *Cancer*, 121(19):3412–3421.
- [16] Pivot, X., Manikhas, A., Åżurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., and others (2015). CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2 – positive metastatic breast cancer. *Journal of Clinical Oncology*, 33(14):1564–1573.
- [17] Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., and Cortes, J. (2015). Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *Journal of clinical oncology*, pages JCO–2013.
- [18] Luck, H.-J., Lubbe, K., Reinisch, M., Maass, N., Feisel-Schwickardi, G., TomÃľ, O., Janni, W., Aydogdu, M., NeunhÃűffer, T., Ober, A., and others (2015). Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. *Breast cancer research and treatment*, 149(1):141–149.
- [19] Martin, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., MuÃśoz, M., and others (2015). Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast

Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. *Journal of Clinical Oncology*, pages JCO–2014.

- [20] Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., and Dieras, V. (2015). Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. *Annals of Oncology*, 26(1):113–119.
- [21] Dieras, V., Campone, M., Yardley, D. A., Romieu, G., Valero, V., Isakoff, S. J., Koeppen, H., Wilson, T. R., Xiao, Y., Shames, D. S., and others (2015). Randomized, phase II, placebocontrolled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. *Annals of Oncology*, 26(9):1904–1910.
- [22] Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., Toppmeyer, D., Carey, L. A., and others (2015). Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063h (Alliance). *Journal of Clinical Oncology*, 33(21):2361–2369.
- [23] Clemens, M. R., Gladkov, O. A., Gartner, E., Vladimirov, V., Crown, J., Steinberg, J., Jie, F., and Keating, A. (2015). Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. *Breast cancer research and treatment*, 149(1):171–179.
- [24] Mackey, J. R., Ramos-Vazquez, M., Lipatov, O., McCarthy, N., Krasnozhon, D., Semiglazov, V., Manikhas, A., Gelmon, K. A., Konecny, G. E., Webster, M., and others (2015). Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. *Journal of Clinical Oncology*, pages JCO–2014.
- [25] Janni, W., Sarosiek, T., Karaszewska, B., Pikiel, J., Staroslawska, E., Potemski, P., Salat, C., Brain, E., Caglevic, C., Briggs, K., and others (2014). A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. *Breast cancer research and treatment*, 143(3):493–505.
- [26] Smorenburg, C. H., de Groot, S. M., van Leeuwen-Stok, A. E., Hamaker, M. E., Wymenga, A. N., de Graaf, H., de Jongh, F. E., Braun, J. J., Los, M., Maartense, E., and others (2014). A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first- line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. *Annals of oncology*, page mdt588.
- [27] Burstein, H. J., Cirrincione, C. T., Barry, W. T., Chew, H. K., Tolaney, S. M., Lake, D. E., Ma, C., Blackwell, K. L., Winer, E. P., and Hudis, C. A. (2014). Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor 2 – Positive Advanced Breast CancerÃćÄĆÅďCALGB 40302 (Alliance). *Journal of Clinical Oncology*, 32(35):3959–3966.
- [28] Kim, S.-B., Yoo, C., Ro, J., Im, S.-A., Im, Y.-H., Kim, J. H., Ahn, J.-H., Jung, K. H., Song, H. S., Kang, S. Y., and others (2014). Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. *Investigational new drugs*, 32(4):753–761.
- [29] Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., and others (2014). Everolimus plus exemestane for hormonereceptor- positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall sur- vival results from BOLERO-2. *Annals of Oncology*, page mdu456.
- [30] O'Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., Robert, N., Hellerstedt, B., Saleh, M., Richards, P., and others (2014). Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology, pages JCO–2014.
- [31] Baselga, J., Manikhas, A., CortÃľs, J., Llombart, A., Roman, L., Semiglazov, V. F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R. H., and others (2014). Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. *Annals of oncology*, 25(3):592–598.
- [32] Crown, J. P., Dieras, V., Staroslawska, E., Yardley, D. A., Bachelot, T., Davidson, N., Wildiers, H., Fasching, P. A., Capitain, O., Ramos, M., and others (2013). Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. *Journal of Clinical Oncology*, pages JCO–2012.
- [33] Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., and others (2013). Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2 – positive metastatic breast cancer. *Journal of Clinical Oncology*, pages JCO–2012.
- [34] Blumenthal, G. M., Scher, N. S., Cortazar, P., Chattopadhyay, S., Tang, S., Song, P., Liu, Q., Ringgold, K., Pilaro, A. M., Tilley, A., and others (2013). First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. *Clinical Cancer Research*, 19(18):4911–4916.
- [35] Park, Y. H., Jung, K. H., Im, S. A., Sohn, J. H., Ro, J., Ahn, J. H., and others (2013). Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. *Journal of Clinical Oncology*, JCO-2012.
- [36] Luck, H.-J., Du Bois, A., Loibl, S., Schrader, I., Huober, J., Heilmann, V., Beckmann, M., StÃďhler, A., Jackisch, C., Hubalek, M., and others (2013). Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. *Breast cancer research and treatment*, 139(3):779–787.
- [37] Kader, Y. A., Spielmann, M., El-Nahas, T., Sakr, A., and Metwally, H. (2013). Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer. *Breast Cancer: Targets and Therapy*, 5:37.
- [38] Harvey, V. J., Sharples, K. J., Isaacs, R. J., Jameson, M. B., Jeffery, G. M., McLaren, B. R., Pollard, S., Riley, G. A., Simpson, A. B., Hinder, V. A., and others (2013). A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. *Annals of oncology*, page mdt065.
- [39] Gianni, L., Romieu, G. H., Lichinitser, M., Serrano, S. V., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, A., Lipatov, O., and others (2013). AVEREL: a randomized phase III Trial eval- uating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2- positive locally recurrent/metastatic breast cancer. *Journal of Clinical Oncology*, 31(14):1719–1725.
- [40] Guan, Z., Xu, B., DeSilvio, M. L., Shen, Z., Arpornwirat, W., Tong, Z., Lorvidhaya, V., Jiang, Z., Yang, J., Makhson, A., and others (2013). Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2 – overexpressing metastatic breast cancer. *Journal of Clinical Oncology*, 31(16):1947–1953.
- [41] Lee, C. K., Gebski, V. J., Coates, A. S., Veillard, A.-S., Harvey, V., Tattersall, M. H., Byrne, M. J., Brigham, B., Forbes, J., Simes, R. J., and others (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. *SpringerPlus*, 2(1):1–10.
- [42] Yamamoto, Y., Ishikawa, T., Hozumi, Y., Ikeda, M., Iwata, H., Yamashita, H., Toyama, T., Chishima, T., Saji, S., Yamamoto-Ibusuki, M., and others (2013). Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. *BMC cancer*, 13(1):239.
- [43] Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., and Trepel, J. B. (2013). Randomized phase II, doubleblind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. *Journal of Clinical Oncology*, 31(17):2128– 2135.
- [44] Curigliano, G., Pivot, X., Cortes, J., Elias, A., Cesari, R., Khosravan, R., Collier, M., Huang, X., Cataruozolo, P. E., Kern, K. A., and others (2013). Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple negative breast cancer. *The Breast*, 22(5):650–656.
- [45] Baselga, J., Gomez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pego, A., Chan, A., and others (2013). Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. *Journal of clinical oncology*, 31(20):2586–2592.
- [46] Fan, Y., Xu, B. H., Yuan, P., Ma, F., Wang, J. Y., Ding, X. Y., Zhang, P., Li, Q., and Cai, R. G. (2013). Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. *Annals of oncology*, page mds603.
- [47] Baselga, J., Segalla, J. G. M., Roche, H., del Giglio, A., Pinczowski, H., Ciruelos, E. M., Cabral Filho, S., Gomez, P., Van Eyll, B., Bermejo, B., and others (2012). Sorafenib in com- bination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. *Journal of clinical oncology*, 30(13):1484–1491.
- [48] Pallis, A., Boukovinas, I., Ardavanis, A., Varthalitis, I., Malamos, N., Georgoulias, V., and Mavroudis, D. (2012). A multicenter randomized phase iii trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. *Annals of oncology*, 23(5):1164–1169.
- [49] Donoghue, M., Lemery, S. J., Yuan, W., He, K., Sridhara, R., Shord, S., Zhao, H., Marathe, A., Kotch, L., Jee, J., and others (2012). Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a "physician's choice" control arm in a randomized approval trial. *Clinical Cancer Research*, 18(6):1496–1505.
- [50] Bergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., and others (2012). First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. *Journal of Clinical Oncology*, pages JCO–2011.
- [51] Hatschek, T., Carlsson, L., Einbeigi, Z., Lidbrink, E., Linderholm, B., Lindh, B., Loman, N., Malm- berg, M., Rotstein, S., Soderberg, M., and others (2012). Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. *Breast cancer research and treatment*, 131(3):939– 947.
- [52] Roche, H., Conte, P., Perez, E. A., Sparano, J. A., Xu, B., Jassem, J., Peck, R., Kelleher, T., and Hortobagyi, G. N. (2011). Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. *Breast cancer research and treatment*, 125(3):755–765.
- [53] Brufsky, A., Hoelzer, K., Beck, T., Whorf, R., Keaton, M., Nadella, P., Krill-Jackson, E., Kroener, J., Middleman, E., Frontiera, M., and others (2011a). A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. *Clinical breast cancer*, 11(4):211–220.
- [54] Xu, B., Jiang, Z., Kim, S.-B., Yu, S., Feng, J., Malzyner, A., del Giglio, A., Chung, H. C., Shen, L. J., and Pen, D. L. K. (2011). Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. *Breast Cancer*, 18(3):203–212.
- [55] Robert, N. J., Saleh, M. N., Paul, D., Generali, D., Gressot, L., Copur, M. S., Brufsky, A. M., Minton, S. E., Giguere, J. K., Smith, J. W., and others (2011b). Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. *Clinical breast cancer*, 11(2):82–92.
- [56] Robert, N. J., Dieras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y., Zhou, X., and others (2011a). RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab

for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. *Journal of Clinical Oncology*, 29(10):1252–1260.

- [57] Brufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., and Rugo, H. S. (2011b). RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of hu- man epidermal growth factor receptor 2–negative metastatic breast cancer. *Journal of Clinical Oncology*, pages JCO–2010.
- [58] Hamberg, P., Bos, M. M., Braun, H. J., Stouthard, J. M., van Deijk, G. A., Erdkamp, F. L., van der Stelt-Frissen, I. N., Bontenbal, M., Creemers, G.-J. M., Portielje, J. E., and others (2011). Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. *Clinical breast cancer*, 11(2):103–113.
- [59] Inoue, K., Nakagami, K., Mizutani, M., Hozumi, Y., Fujiwara, Y., Masuda, N., Tsukamoto, F., Saito, M., Miura, S., Eguchi, K., and others (2010). Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as firstline therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. *Breast cancer research and treatment*, 119(1):127–136.
- [60] Sparano, J. A., Vrdoljak, E., Rixe, O., Xu, B., Manikhas, A., Medina, C., Da Costa, S. C. V., Ro, J., Rubio, G., Rondinon, M., and others (2010). Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *Journal of clinical oncology*, pages JCO–2009.
- [61] Barrios, C. H., Liu, M.-C., Lee, S. C., Vanlemmens, L., Ferrero, J.-M., Tabei, T., Pivot, X., Iwata, H., Aogi, K., Lugo-Quintana, R., and others (2010). Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. *Breast cancer research and treatment*, 121(1):121–131.
- [62] Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., and others (2010). Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. *Journal of Clinical Oncology*, 28(7):1124–1130.
- [63] Moulder, S. L., Holmes, F. A., Tolcher, A. W., Thall, P., Broglio, K., Valero, V., Buzdar, A. U., Arbuck, S. G., Seidman, A., and Hortobagyi, G. N. (2010). A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. *Cancer*, 116(4):814–821.
- [64] Clemons, M., Joy, A. A., Abdulnabi, R., Kotliar, M., Lynch, J., Jordaan, J. P., Iscoe, N., and Gelmon, K. (2010). Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. *Breast cancer research and treatment*, 124(1):177–186.
- [65] Ruff, P., Vorobiof, D. A., Jordaan, J. P., Demetriou, G. S., Moodley, S. D., Nosworthy, A. L., Werner, I. D., Raats, J., and Burgess, L. J. (2009). A randomized, placebo-controlled, doubleblind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women

with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. *Cancer chemotherapy and pharmacology*, 64(4):763–768.

- [66] Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., and others (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor–positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. *Journal of Clinical Oncology*, 27(33):5529–5537.
- [67] Cassier, P. A., Chabaud, S., Trillet-Lenoir, V., Peaud, P.-Y., Tigaud, J.-D., Cure, H., Orfeuvre, H., Salles, B., Martin, C., Jacquin, J.-P., and others (2008). A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. *Breast cancer research and treatment*, 109(2): 343–50.
- [68] Aapro, M., Leonard, R. C., Barnadas, A., Marangolo, M., Untch, M., Malamos, N., Mayordomo, J., Reichert, D., Pedrini, J. L., Ukarma, L., et al. (2008). Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the breast cancerÃćÄĆÅďanemia and the value of erythropoietin (brave) study. *Journal of Clinical Oncology*, 26(4):592–598.
- [69] Rivera, E., Mejia, J. A., Arun, B. K., Adinin, R. B., Walters, R. S., Brewster, A., Broglio, K. R., Yin, G., Esmaeli, B., Hortobagyi, G. N., and others (2008). Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. *Cancer*, 112(7):1455–1461.
- [70] Crump, M., Gluck, S., Tu, D., Stewart, D., Levine, M., Kirkbride, P., Dancey, J., OâĂŹReilly, S., Shore, T., Couban, S., and others (2008). Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA. 16. *Journal of Clinical Oncology*, 26(1):37–43.
- [71] Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., and Davidson, N. E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *New England Journal of Medicine*, 357(26):2666–2676.
- [72] Kroger, N., Frick, M., Gluz, O., Mohrmann, S., Metzner, B., Jackisch, C., Ko, Y., Lindemann, H.- W., Meier, C. R., Lohrmann, H. P., and others (2006). Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. *Journal of clinical oncology*, 24(24):3919– 3926.
- [73] Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., and others (2005). Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *Journal of Clinical Oncology*, 23(4):792–799.
- [74] Sparano, J. A., Bernardo, P., Stephenson, P., Gradishar, W. J., Ingle, J. N., Zucker, S., and Davidson, N. E. (2004). Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Coop- erative Oncology Group trial E2196. *Journal of Clinical Oncology*, 22(23):4683– 4690.
- [75] Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., and others (2004). Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. *Journal of Clinical Oncology*, 22(19):3893– 3901.
- [76] O'brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., and others (2004). Reduced cardiotoxicity and compa- rable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Annals of oncology*, 15(3):440–449.
- [77] van der Hage, J. A., van de Velde, C. J., Julien, J.-P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., and Investigators, C. (2001). Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Journal of Clinical Oncology, 19(22):4224–4237.
- [78] Klijn, J. G., Beex, L. V., Mauriac, L., van Zijl, J. A., Veyret, C., Wildiers, J., Jassem, J., Piccart, M., Burghouts, J., Becquart, D., and others (2000). Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. *Journal of the National Cancer Institute*, 92(11):903–911.
- [79] Zhou, X.-H., McClish, D. K., and Obuchowski, N. A. (2009). *Statistical methods in diagnostic medicine*, volume 569. John Wiley & Sons.
- [80] Breiman, L., Friedman, J., Stone, C. J., and Olshen, R. A. (1984). *Classification and regression trees.* CRC press.
- [81] Youden, W. J. (1950). Index for rating diagnostic tests. *Cancer*, 3(1):32–35.
- [82] Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005). ROCR: visualizing classifier perfor- mance in R. *Bioinformatics*, 21(20):7881.
- [83] Therneau, T., Atkinson, B., and Ripley, B. (2015). *rpart: Recursive Partitioning and Regression Trees*. R package version 4.1-9.
- [84] Liaw, A. and Wiener, M. (2002). Classification and regression by randomforest. R News, 2(3):18– 22.
- [85] Johnson, J. R., Williams, G., and Pazdur, R. (2003). End points and united states food and drug administration approval of oncology drugs. *Journal of Clinical Oncology*, 21(7):1404–1411.
- [86] EMEA CHMP (2007). Methodological considerations for using progression-free survival (pfs) as primary endpoint in confirmatory trials for registration.